HUMAN COMPLEMENT FACTOR H RELATED PROTEIN TEST FOR MONITORING BLADDER CANCER
Authors:
- Pentti NieminenPentti Nieminen
- FINNBLADDER GROUPFGFINNBLADDER GROUP
- 1 February 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 165 (2) , 374-377
Abstract
The BTA stat test is a rapid, noninvasive, qualitative urine test that detects bladder tumor associated antigen (human complement factor H related protein) in urine. We compared BTA stat test to voided urine cytology in patients monitored for bladder cancer in a prospective trial, and determined whether this test is effective in detection of recurrence not seen by regular cystoscopy. A total of 445 consecutive patients with bladder cancer were studied. A voided urine sample was obtained before cystoscopy and divided for culture, cytology and BTA stat testing. In cases of a positive BTA stat test but negative cystoscopy, excretory urography or renal ultrasound, random biopsies and collected ureteral urine samples for ureteral cytology were obtained. The overall sensitivity and specificity as well as positive and negative predictive values for BTA stat test, cytology and their combination were calculated. Of the 445 patients 118 (26.5%) had bladder cancer recurrence on cystoscopy, which was detected by BTA stat test and cytology in 63 (53.4%) and 21 (17.8%), respectively. Of the remaining 327 patients not having recurrent tumor on cystoscopy 81 (24.8%) had a positive BTA stat test. Excretory urography or renal ultrasound and random biopsies in 48 (59.3%) of these patients revealed 7 recurrences, making the total number of recurrent tumors 125 of 412 (30.3%). The overall sensitivities and specificities for the BTA stat test, cytology and their combination were 56.0%, 19.2%, 60.0% and 85.7%, 98.3% and 85.0%, respectively. The sensitivity for detection of recurrent tumor on BTA stat test is superior to that of voided urine cytology in all bladder cancer categories, whereas the specificity of voided urine cytology is higher than that for BTA stat test. However, a sixth of the patients with apparent false-positive BTA stat test results chosen for further investigation had recurrent tumors that were not found on routine cystoscopy. Although the sensitivity and specificity were highest when both tests were used, the differences were not significant overall. Therefore, the BTA stat test could potentially replace urine cytology for followup of superficial bladder cancer.Keywords
This publication has 14 references indexed in Scilit:
- SENSITIVITY OF HUMAN COMPLEMENT FACTOR H RELATED PROTEIN (BTA STAT) TEST AND VOIDED URINE CYTOLOGY IN THE DIAGNOSIS OF BLADDER CANCERJournal of Urology, 2000
- NONINVASIVE DETECTION OF BLADDER CANCER WITH THE BTA STAT TESTJournal of Urology, 1999
- Comparison of the BTA statTM Test with Voided Urine Cytology and Bladder Wash Cytology in the Diagnosis and Monitoring of Bladder CancerEuropean Urology, 1999
- Specificity of Human Complement Factor H-Related Protein Test (Bard BTA stat Test)Scandinavian Journal of Urology and Nephrology, 1999
- Improved detection of recurrent bladder cancer using the bard bta stat testUrology, 1997
- Superficial bladder cancer: for how long should a tumour‐free patient have check cystoscopies?British Journal of Urology, 1995
- Current status of urinary cytology in the evaluation of bladder neoplasmsHuman Pathology, 1990
- Ta and T1 Bladder Cancer: Location, Recurrence and Progression†British Journal of Urology, 1982
- Prognostic Parameters in Superficial Bladder Cancer: An Analysis of 315 CasesJournal of Urology, 1982
- Urine Sediment Smears as a Diagnostic Procedure in Cancers of the Urinary TractScience, 1945